The prognostic value of the 8th edition of the American Joint Committee on Cancer (AJCC) staging system in triple-negative breast cancer.
The American Joint Committee on Cancer (AJCC) released its 8th edition of cancer staging which is to be implemented in early 2018. This study aims to compare anatomic staging (AS) with prognostic staging (PS) based on the updated AJCC 8th edition staging manual. A retrospective single-center analysis of 313 triple-negative breast invasive ductal carcinoma patients who received surgery at department of breast surgery in the Fourth Hospital of Hebei Medical University from 2010-01 to 2012-12 was performed. All cases were restaged using the AJCC 8th edition AS and PS system. The 7-year DFS and the 7-year OS rates were 76.30% and 78.27%, respectively. Applying the PS system, 277 (88.5%) patients of the AS groups were up-staged to the PS groups, 31 cases with IIIC and 5 cases with IV unchanged (11.5%), and no cases down-staged. Both 7-year DFS and 7-year OS were significantly different in the different AS and PS groups (all, P<0.001). The PS system was found to provide better prognostic information in patients with AS group IIB. A total of 43 patients with AS group IIB were up-staged by PS system, in which 30 patients were +2 up-staged to PS IIIB, and 13 patients were +3 up-staged to PS IIIC. PS IIIB and IIIC from AS IIB had significant differences in 7‑year DFS (χ2 = 5.628, P = 0.014) and 7‑year OS (χ2 = 6.037, P = 0.018). Both AS and PS systems proposed in the 8th edition of the AJCC breast cancer staging manual had prognostic value in TNBC. Moreover, the PS system predicts clinical outcomes of TNBC patients more accurately than the traditional AS system.